Movalis active ingredient. Composition, forms of release, packaging. Indications for use

Thanks

Description

• tablets;
• rectal suppositories;
• solution for intramuscular injection.

pharmachologic effect

Most of the active substance that enters the body binds to albumin. Meloxicam enters the inflamed organs through the so-called histohematic barriers. Meloxicam is metabolized in the liver.

Indications for use

• with arthrosis;
• with osteoarthritis;
• with osteochondrosis;
• with degenerative changes in the joints.

Instructions for use of tablets, suppositories and injection solution
(shots)

1. The standard dose is usually 7.5 mg once a day. In each individual case, the dosage is calculated depending on how intensely the pain is expressed and how severe the inflammatory processes are.
2. The maximum allowable daily dose is 15 mg. High dosage can lead to the development of undesirable effects, so it is recommended to choose the lowest effective dose.
3. The total daily dose of Movalis, used in the form of several dosage forms (suppositories, injections, tablets), should not exceed 15 mg.

In persons with renal insufficiency, who undergo hemodialysis, the dosage of Movalis should not exceed the standard (7.5 mg).

Movalis for osteochondrosis

Side effects

1. Digestive system: flatulence, epigastric pain, nausea, belching, colitis, ulcerative formations in the gastrointestinal tract.
2. Hematopoietic system: leukopenia, thrombocytopenia.
3. Skin reactions: itching, urticaria, photosensitivity, stomatitis.
4. Respiratory system: acute attack of bronchial asthma.
5. Nervous system: drowsiness, tinnitus, dizziness, irritability.
6. The cardiovascular system: swelling, pressure changes, hot flashes.
7. Vision: conjunctivitis.

Contraindications

• peptic ulcer;
• taking anticoagulants;
• severe liver or kidney failure;
• "aspirin triad" (this term refers to the combination of polypous rhinosinusitis with bronchial asthma and aspirin intolerance);
• inflammatory diseases of the rectum (this contraindication applies to the use of rectal suppositories);
• old age and childhood.

Movalis during pregnancy

Mydocalm, Milgamma

Diclofenac, or what can replace Movalis?

Thanks to Diclofenac, in patients:
1. Reduces pain in rheumatic diseases.
2. Increased range of motion.
3. Eliminates swelling and morning stiffness of the joints.

This drug, like Movalis, belongs to the group of non-steroidal anti-inflammatory drugs, although it has a different active ingredient. Both drugs are available in the same dosage forms.

These drugs can replace each other in the treatment of disorders of the musculoskeletal system. However, the prescription of the drug should only come from a doctor. Self-assignment is not allowed.

Several years ago, a six-month comparative study of Movalis and Diclofenac was conducted. 335 patients were examined, who complained of pain in the hip joints, swelling of the knee joints. In terms of effectiveness, both drugs have proven to be the same. But the side effects that were observed in both experimental groups had a different frequency of occurrence. If Movalis influenced the development of side effects in 11% of patients, then Diclofenac - in 14%.

Movalis and alcohol

Interaction

• The drug may reduce the effectiveness of the intrauterine device.
• The drug in combination with diuretics: patients should drink plenty of fluids and regularly check kidney function.
• The drug reduces the effectiveness of drugs that normalize blood pressure.

Overdose

Release form - tablets, ampoules, suppositories (suppositories)

1. Injection:

• N-methyl-D-glucamine;
• glycofurol;
• sodium hydroxide;
• sodium chloride;
• Pluronic F68.

• sodium citrate;
• povidone;
• anhydride colloidal silicon dioxide;
• lactose;
• magnesium stearate;

• macrogol glyceryl hydroxystearate;
• suppository mass.

Features of the use of various dosage forms of Movalis

Injections (shots)

Tablets

Tablets differ from the solution for parenteral administration in that they act on the body more gently and slowly. Therefore, with severe pain, they are prescribed in combination with injections. In the event that pain and inflammation are moderately expressed, only tablets can be used.

Candles (rectal suppositories)

Additional instructions

The drug can affect the reaction rate and alertness. When using it, it is undesirable to drive a car or engage in work that requires high accuracy of actions.

Analogues

• Meloxicam;
• Amelotex;
• Movasin;
• Movix;
• Artrozan;
• Bi-xicam;
• Matarin;
• M-Kam;
• Melbek forte;
• Melbeck;
• Meloflam;
• Melox;
• Mesipol.

Movalis is a drug that is available in the form of ampoules with a solution for injection, suppositories for rectal use and tablets. Indications for the use of the drug Movalis are inflammatory processes in the bones and muscles of the human body. Movalis tablets have a round shape and a slightly rough surface. The color of the tablets may vary from pale yellow to yellow. One of the sides of the tablets is convex, the manufacturer's logo is placed on it. Movalis rectal suppositories have a smooth surface, their base is slightly deepened. The solution for injection is produced in ampoules of 15 milligrams each and has a yellowish-green color. The medicine Movalis is an effective remedy for high temperature, acute pain syndromes and inflammatory processes, and its indications for use are quite diverse. The drug is recommended for arthritis, osteoarthritis, spondylitis and other diseases of the musculoskeletal system, accompanied by acute pain. The medicine also has contraindications, which differ for each type of drug.

The medicine Movalis in the form of tablets has the following indications for use:

• inflammation of the joints, autoimmune diseases of connective tissues;
• degenerative-dystrophic diseases of the musculoskeletal system.

The main constituent of the tablets is meloxicam, which, when administered internally, is absorbed in the body, concentrating in the synovial fluid. The advantage of this form of the drug is that the tablets act mainly on cyclooxygenase-2, which helps to avoid negative effects on the gastrointestinal tract. It is recommended to take the tablets once a day, preferably with meals. It is strictly forbidden to drink the medicine with any liquid other than water. Indications for the use of the drug Movalis are diverse in various diseases: in osteoarthritis, the daily dose is 7.5 mg, and in other inflammatory diseases with pain syndrome - 15 mg.

• renal and liver failure;
• acute inflammation of the stomach;
• stomach and duodenal ulcer;
• pronounced diseases of the cardiovascular system.

In any situation, the decision to prescribe the drug should be made by the attending physician. The information provided is for informational purposes only.

What does Movalis look like?

Candles Movalis

Indications for the use of the drug Movalis in the form of rectal suppositories include not only arthritis, endometritis, arthrosis and osteochondrosis, but also hemorrhoids, various inflammatory processes of the genital organs, as well as pain syndromes in gynecological diseases in women. With rectal use of the drug, its main component, meloxicam, is absorbed into the bloodstream, bypassing the gastrointestinal tract, which allows the drug to act on the focus of inflammation much faster than when using tablets.

The medicine Movalis in the form of suppositories has the following indications for use: 7.5 mg no more than once a day. However, in the acute stages of inflammatory processes, as well as with severe pain, the daily dose of the drug can be increased to 15 mg.

It is forbidden to use rectal suppositories in the following cases:

• damage or cracks in the anus;
• the last trimester of pregnancy and the period of breastfeeding;
• pathological processes in the kidneys and liver;
• inflammatory processes of the gastrointestinal tract;
• bleeding from the rectum.

Movalis in the form of injections

Indications for the use of Movalis in the form of injections include short-term treatment of acute attacks of arthritis and spondylitis, in cases where the use of tablets or suppositories is impossible due to any circumstances. With the introduction of the Movalis solution into the patient's muscle, the latter feels pain relief after thirty to forty minutes, since in this case meloxicam is quickly absorbed and concentrated in the plasma. However, this type of treatment can be used only during the first few days of therapy, and then it should be replaced with tablets or rectal suppositories.

The medicine Movalis in the form of injections has the following indications for use: the drug should be administered once a day intramuscularly, dosing the drug from 7.5 to 15 mg, depending on the intensity of the patient's pain. The drug is prohibited for use in the following diseases:

• gastrointestinal bleeding;
• severe hepatic and renal failure;
• diseases of the cardiovascular system;
• postoperative pain during coronary bypass surgery;
• cerebrovascular bleeding.

Analogues of the drug Movalis

Indications for the use of the drug Movalis are quite extensive, however, due to its significant cost, this drug is not available to every consumer. That is why, after consulting a doctor, you can purchase analogues of this medicine (that is, drugs that have the same international non-proprietary name). Indications for the use of Movalis analogues include symptomatic treatment of arthritis, arthrosis, spondylitis, Bechterew's disease, gout and neuralgia. All analogues of Movalis have anti-inflammatory, analgesic and anti-inflammatory effects. Analogues are produced as well as Movalis himself, in the form of tablets, injections and rectal suppositories.

Movalis analogues include the following drugs:

• Meloxicam, Meloxicam-Prana, Meloxicam Sandoz and Meloxicam-Teva;
• Artrozan;
• Amelotex;
• Movasin;
• Movix;
• Bi-xicam;
• Aspicam;
• Brexin;
• Zeloxim;
• Movalgin;
• Texamen;
• Fedin;
• Matarin;
• Melbek and Melbek forte.

The price range is large. The cost is determined by the country where the drug is produced (imported ones are more expensive, of course), the high cost of raw materials, and the authority of the brand.

The composition of the medicinal product Movalis

in colorless glass ampoules type I, 1.5 ml each, in a blister pack of 3 or 5 ampoules; in a pack of cardboard 1 pack.
Tablets 1 tab.
active substance:
meloxicam 7.5 mg
15 mg
excipients: sodium citrate; lactose; MCC; povidone (collidone 25), colloidal silicon dioxide; crospovidone; magnesium stearate

in a blister 10 pcs.; in a pack of cardboard 1 or 2 blisters.
Suppositories for rectal use 1 supp.
active substance:
meloxicam 7.5 mg
15 mg
excipients: suppository mass (suppocir BP), macrogol glyceryl hydroxystearate (polyethylene glycol glyceryl hydroxystearate - cremophor RH40)

in blister packs of 6 pcs.; in a box 1 or 2 packs.

Dosage form

Pharmacotherapeutic group

Pharmacological properties

Pharmakinetics:
Distribution
The active substance of the drug binds to plasma proteins by 99 percent. Penetration into inflamed organs occurs through histohematic barriers.

Metabolism
Metabolization occurs in the liver.

breeding
Occurs within 20 hours of ingestion. About 5 percent of the daily dose of the drug passes unchanged through the intestines

Indications for use Movalis

Contraindications

A contraindication for injectable movalis is the patient taking anticoagulants, as this can provoke the development of intramuscular hematomas.
Rectal administration of the drug is highly undesirable in inflammatory diseases of the rectum and anal region.
Contraindications for taking the drug are also old age, pregnancy and lactation.

Usage Precautions

Interaction with drugs

The drug for injection should not be mixed in one syringe with others.
With the simultaneous administration of anatacids, cimetidan, digoxin, furosemide with meloxicam, no pharmacokinetic drug interactions were identified.

Method of application and dosage Movalis

In / m administration of the drug is indicated only during the first 2-3 days of therapy. In the future, treatment is continued with the use of enteral forms. The recommended dose is 7.5 mg or 15 mg 1 time per day, depending on the intensity of pain and the severity of the inflammatory process.

The drug is administered by deep intramuscular injection.

Given the possible incompatibility, the contents of Movalis® ampoules should not be mixed in the same syringe with other drugs.

Kidney dysfunction. In patients with severe renal insufficiency on hemodialysis, the dose should not exceed 7.5 mg / day.

The drug should not be administered intravenously.

Inside, during meals, drinking water or other liquid; rectally.

Osteoarthritis, rheumatoid arthritis - 7.5 mg / day. If necessary, this dose can be increased to 15 mg / day. Depending on the therapeutic effect, this dose can be reduced to 7.5 mg / day.

Ankylosing spondylitis - 15 mg / day. Depending on the therapeutic effect, this dose can be reduced to 7.5 mg / day.

In patients with an increased risk of adverse reactions, it is recommended to start treatment with a dose of 7.5 mg / day. For patients with severe renal insufficiency on hemodialysis, the dose should not exceed 7.5 mg / day.

Teenagers

The maximum dose for adolescents is 0.25 mg/kg.

As a rule, the drug should only be used in adolescents and adults (see section "Contraindications"). The maximum recommended daily dose is 15 mg.

Due to the fact that the risk of adverse reactions depends on the dose and duration of use, the drug should be used for the shortest possible time at the lowest possible effective dose.

Combined application. The total daily dose of Movalis®, used in the form of tablets, suppositories, injections, should not exceed 15 mg.

Side effects

Digestive system:
Nausea, vomiting, abdominal pain, flatulence, diarrhea, constipation can be experienced by up to 5 percent of those taking the drug. Other symptoms (such as belching, esophagitis, gastrointestinal ulcers, occult or macroscopic gastrointestinal hemorrhages, colitis and gastritis) are experienced by less than 0.1 percent.

Hematopoietic system:
Occasionally, the use of the drug can provoke anemia, even less often - leukopenia, thrombocytopenia, contributes to a change in the number of individual types of leukocytes per unit of measurement.

Skin reactions:
Itching, rash, stomatitis, urticaria, photosensitivity.
In some cases, an allergic reaction may occur.

Respiratory system:
Extremely rarely there can be acute attacks of bronchial asthma.

Nervous system:
Headaches, dizziness, tinnitus, drowsiness, mood swings, nervousness.
The cardiovascular system:
Edema, changes in blood pressure, hot flashes and palpitations.

Vision:
Visual impairment and conjunctivitis.

Overdose

Storage conditions

Product group

Non-steroidal anti-inflammatory drug - NSAID

Release form

• 1.5 ml - colorless glass ampoules (3) - contour plastic pallets (1) - cardboard boxes. 1.5 ml - colorless glass ampoules (5) - contour plastic trays (1) - cardboard boxes. 1.5 ml - colorless glass ampoules (3) - contour plastic trays (1) - cardboard boxes. 1.5 ml - colorless glass ampoules (5) - contour plastic trays (1) - cardboard boxes. 1.5 ml - colorless glass ampoules (5) - contour plastic pallets (1) - cardboard boxes 10 - blisters (1) - cardboard packs. 10 - blisters (2) - packs of cardboard. 10 - blisters (1) - packs of cardboard. 10 - blisters (2) - packs of cardboard. 10 - blisters (1) - packs of cardboard. 10 - blisters (2) - packs of cardboard. 100 ml - dark glass bottles (1) complete with dosing spoon - packs of cardboard. 5 packs of 10 ampoules 6 - contour packs (1) - packs of cardboard. 6 - contour packages (2) - packs of cardboard.

Description of the dosage form

• Solution for i / m administration is transparent, yellow with a green tint. Solution for i / m is transparent, yellow with a green tint. The solution for i / m administration is transparent, yellow with a green tint. Rectal suppositories are smooth, yellowish-green in color, with a depression at the base. Suspension for oral administration Pale yellow to yellow tablets, round, one side is convex with a bevelled edge, on the convex side - the company's logo, on the other side - a concave line, on both sides of which "77C" is engraved. Tablets from pale yellow to yellow, round, one side is convex with a bevelled edge, on the convex side there is a company logo, on the other side there is a code and a concave risk mark; roughness of tablets is allowed.

pharmachologic effect

Pharmacokinetics

Special conditions

Compound

• 1 amp. meloxicam 15 mg Excipients: meglumine - 9.375 mg, glycofurfural - 150 mg, poloxamer 188 - 75 mg, sodium chloride - 4.5 mg, glycine - 7.5 mg, sodium hydroxide - 228 mcg, water for injection - 1279.482 mg. 1 tab. meloxicam 7.5 mg Excipients: sodium citrate dihydrate - 15 mg, lactose monohydrate - 23.5 mg, microcrystalline cellulose - 102 mg, povidone K25 - 10.5 mg, colloidal silicon dioxide - 3.5 mg, crospovidone - 16.3 mg, magnesium stearate - 1.7 mg. 1 supp. meloxicam 7.5 mg Excipients: suppository mass (suppository BP), macrogol glyceryl hydroxystearate (polyethylene glycol glyceryl hydroxystearate). meloxicam 15 mg Excipients: sodium citrate, lactose, microcrystalline cellulose, povidone (collidon 25), colloidal silicon dioxide, crospovidone, magnesium stearate. Meloxicam 7.5 mg; Auxiliary substances: colloidal silicon dioxide, hyetylose, sorbitol 70%, glycerol 85%, xylitol, sodium saccharinate, sodium benzoate, citric acid monohydrate, flavor Movalis raspberry solution for intramuscular injection 1 ml: meloxicam 10 mg Excipients: meglumine - 9.375 mg, glycofurfurol - 150 mg, poloxamer 188 - 75 mg, sodium chloride - 4.5 mg, glycine - 7.5 mg, sodium hydroxide - 228 mcg, water for injection - 1279.482 mg.

Movalis indications for use

• Initial therapy and short-term symptomatic treatment for: osteoarthritis (arthrosis, degenerative joint diseases); rheumatoid arthritis; ankylosing spondylitis; other inflammatory and degenerative diseases of the musculoskeletal system such as arthropathy. dorsopathy (for example, sciatica, lower back pain, shoulder periarthritis and others), accompanied by pain.

Movalis contraindications

• - a combination of bronchial asthma, recurrent polyposis of the nose and paranasal sinuses and intolerance to acetylsalicylic acid and pyrazolone drugs; - peptic ulcer / perforation of the stomach and duodenum in the acute stage or recently transferred; - inflammatory bowel disease - Crohn's disease or ulcerative colitis in the acute stage; - severe liver failure; - severe renal failure, chronic renal failure in patients not undergoing hemodialysis with KK

Movalis dosage

• 15 mg 15 mg/1.5 ml 7.5 mg 7.5 mg, 15 mg

Movalis side effects

• The following describes the side effects, the relationship of which with the use of the drug Movalis® was regarded as possible. Side effects registered during post-marketing use, the relationship of which with the use of the drug was regarded as possible, are marked with *. Within the systemic organ classes, the following categories are used in terms of the incidence of side effects: very often (?1/10); often (?1/100,

drug interaction

Overdose

Storage conditions

• store at room temperature 15-25 degrees
• keep away from children
• store in a place protected from light

Synonyms

• Lem, Melbek, Melbek forte, Melox, Meloxicam, Movasin, Artrozan

Movalis tablets is an anti-inflammatory non-steroidal drug, which is a derivative of enolic acid. The drug has analgesic, anti-inflammatory, antipyretic effect. The strong antiphlogistic effect of meloxicam has been established in every standard model of inflammation.

The principle of action of the drug, the active substance of which is meloxicam, is to suppress the synthesis of prostaglandins - inflammatory mediators. In vivo, meloxicam slows down the synthesis of prostaglandins in the area of ​​inflammation much more than in the kidneys or gastric mucosa.

These differences are associated with a strong selective inhibition of COX-2 in comparison with COX-1. Presumably, inhibition of COX-2 has a therapeutic effect of NSAIDs, while inhibition of the COX-1 isoenzyme can provoke side effects that extend to the functioning of the kidneys and stomach.

Indications Ex vivo found that the active substance of the drug, subject to the recommended dosage, did not affect the bleeding period and platelet aggregation in comparison with:

• naproxen;
• indomethacin;
• ibuprofen;
• diclofencom.

These drugs significantly inhibit platelet aggregation and increase bleeding time.

After conducting clinical studies, it turned out that the side effects associated with the work of the gastrointestinal tract in the case of taking 7.5 mg and 15 mg of meloxicam were less common in comparison with taking NSAIDs.

The difference in the intensity of side effects in the gastrointestinal tract, as a rule, is based on the fact that if you take meloxicam 15 mg, complications manifested by abdominal pain, dyspepsia, nausea and vomiting are not so common.

The instruction for the use of the drug states that the intensity of perforations in the gastrointestinal tract, bleeding and ulcers associated with taking meloxicam was not high and was based on the dosage of the drug.

Pharmacokinetics and indications for use

Movalis tablets are well absorbed from the gastrointestinal tract. This is proven by the high and absolute bioavailability (89%) when taken orally. Eating food combined with taking tablets does not affect the absorption of the drug.

Meloxicam is almost completely metabolized in the liver. In this case, 4 pharmacologically passive derivatives are formed. It is excreted evenly with urine and feces, usually in the form of metabolites.

Part (5%) of the daily dose of the drug is excreted with the feces, and in the urine the unchanged part of the drug can be detected only in a trace volume.

Symptomatic therapy:

• rheumatoid arthritis;
• osteoarthritis.

That is, indications for the use of Movalis are degenerative joint diseases and arthrosis.

Release form:

1. rectal suppositories - 7.5/15 mg;
2. tablets - 7.5 / 15 mg;
3. suspension for internal use;
4. solution in ampoules intended for intramuscular injection (for injections) 1.5 ml.

Dosage and instructions for use

With arthrosis (osteoarthritis), the daily dosage should be no more than 7.5 mg. If necessary, the doctor can increase the daily dose to 15 mg.

With ankylosing spondylitis and rheumatoid arthritis, the drug is prescribed at 15 mg per day, and when a positive effect is achieved, the dosage can be reduced to 7.5 mg.

Important! For people who are likely to develop side effects, it is better to start taking the drug with a dosage of 7.5 mg.

For patients with renal insufficiency who are on hemodialysis, the daily dosage of Movalis should not be more than 7.5 mg.

And how many mg of Movalis should be taken in adolescence? Adolescents should take the drug at a rate of 0.25 mg per 1 kg of body weight. The maximum dosage of the drug for 1 day is 15 mg.

The medicine is taken during a meal while it should be washed down with water.

Due to the fact that the appearance of side effects is associated with the volume of the dose and the duration of the application, the drug should be used for a short time and most likely at a low effective dosage.

The daily amount of taking tablets, solution and suspensions of Movalis should be no more than 15 mg.

Side effects

An increased dose, incorrect intake and individual intolerance can cause side effects, as a result of which there will be:

• visual impairment;
• changes in the leukocyte formula;
• conjunctivitis (shown in the photo);
• anemia;
• glomerulonephritis;
• thrombocytopenia;
• acute renal failure;
• leukopenia;
• frequent heartbeat;
• migraine;
• high blood pressure;
• dizziness;
• bronchial asthma;
• noise in ears;
• photosensitivity;
• drowsiness;
• mood swings;
• perforation of the gastrointestinal tract;
• hives;
• bleeding that occurs in the intestines and stomach, which can be fatal;
• skin rashes;
• gastroduodenal ulcers;
• angioedema;
• colitis;
• flatulence;
• gastritis;
• constipation;
• esophagitis;
• vomiting, nausea;
• stomatitis;
• diarrhea;
• stomach ache.

Contraindications for use

Despite the indications (arthritis, arthrosis) for use, the instructions for the drug states that it should not be taken in the presence of peptic ulcer, duodenal perforation and gastric ulcer, which are at an acute stage. Also, you can not take Movalis in the presence of Crohn's disease or ulcerative colitis, which is in the acute stage.

Moreover, the medicine should not be taken with bronchial asthma, urticaria (as in the photo), nasal polyposis, angioedema, and after taking aspirin or other NSAIDs in history. Uncontrolled severe cardiac, severe renal (hemodialysis) and liver failure, pregnancy, lactation can also become an obstacle to taking Movalis.

Also, the instructions for use states that the medicine should not be taken after suffering cerebrovascular bleeding or diagnosing a disease of the blood coagulation system and with acute bleeding occurring in the stomach and intestines.

High sensitivity to the active substance of Movalis or its other components (there is a risk of cross-sensitivity to ACC and other NSAIDs), treatment of perioperative pain or coronary artery bypass surgery and age up to 12 years (with the exception of rheumatoid arthritis) are significant reasons due to which you should stop taking the drug.

With extreme caution, it is necessary to take Movalis in the presence of gastrointestinal disease (in history), renal and heart failure, prolonged use of NSAIDs and frequent drinking.

In addition, Movalis is undesirable in diabetes mellitus, coronary artery disease, cerebrovascular diseases, and hyperlipidemia.

In addition, smokers and the elderly and those who have peripheral arterial disease and dyslipidemia should be careful with the use of the drug.

Use in lactation and pregnancy

The use of Movalis during breastfeeding and pregnancy should be treated with extreme caution.

Also, the drug inhibits cyclooxygenesis and the synthesis of prostaglandins, so it can affect fertility. Therefore, it should not be taken by women who are planning a pregnancy.

special instructions

Patients with gastrointestinal diseases should be systematically observed by a doctor. In the event of an ulcer or bleeding of the gastrointestinal tract, Movalis should be discontinued.

Peptic ulcer disease, bleeding, and perforation may occur at any time during treatment, as well as with suspicious symptoms or a history of complications and in the absence of any symptoms. As a rule, serious consequences occur in people who are in old age.

With special care, it is necessary to treat Movalis to people who develop adverse events associated with the mucous membrane, skin and have high sensitivity reactions to the agent. In particular, if reactions of this kind were manifested during past courses of therapy.

The occurrence of such reactions can be observed in the first 30 days of treatment. In this case, the doctor may prohibit the patient from taking Movalis.

Also, like other NSAIDs, tablets, solution and injections of meloxicam increase the likelihood of developing cardiovascular thrombosis, myocardial infarction and an angina attack, which can even lead to death.

Also, the likelihood of complications increases with prolonged use of the drug and in people with a history of the above diseases and in those who have a predisposition to these diseases.

NSAIDs slow down the process of synthesizing prostaglandins in the kidneys, which are actively involved in supporting renal perfusion. The use of NSAIDs in people with minimal renal blood flow or reduced BCC leads to decompensated renal failure, which occurs in a latent form.

Cancellation of NSAIDs will help restore kidney function. Often, the likelihood of developing such a reaction is typical for older people and for those who have been noted:

• dehydration;
• cirrhosis of the liver;
• congestive heart failure;
• failure of the kidneys;
• nephrotic syndrome.

Also, the phenomenon can develop in people who have undergone surgery, leading to hypovolemia and in those who have taken diuretic drugs. Such people at the initial stage of treatment need to monitor the work of the kidneys and control diuresis.

Taking NSAIDs in combination with diuretics often leads to water retention of potassium and sodium in the body and to a decrease in the natriuretic effect of diuretics. As a result, in patients with a predisposition, symptoms of hypertension and heart failure may increase.

Consequently, the health status of such patients must be constantly monitored, and it is also important that such a person maintains adequate hydration. In this case, before starting therapy, it is necessary to conduct a study of kidney function. Conducting combined therapy, it is also necessary to monitor the work of the kidneys.

In the case of using Movalis, an episodic indicator of transaminase or other indicators of liver function in the blood serum was noticed. But in general, the rise in the level was insignificant and transient. In the event that the changes turn out to be more significant or do not go away in the future, then Movalis should be canceled and a study should be carried out for the established laboratory changes.

People who are emaciated or in a weakened state tolerate complications much worse; for these reasons, such patients need to be constantly monitored.

Note! Meloxicam may mask symptoms infectious disease.

People with hereditary glucose intolerance, lapp lactase deficiency or galactose/glucose malabsorption should not take this medicine.

With simultaneous internal administration of anticoagulants, heparin, ticlopidine, thrombolytic drugs, the effect of anticoagulants should be carefully monitored.

Special studies that determine the degree of influence of the drug on the ability to control transport and other mechanisms have not been conducted. However, it is better to refuse driving for people who are in a sleepy state and for those who have visual and nervous system impairments.

Interaction with other drugs

When combined with meloxicam, other inhibitors of prostaglandin synthesis, namely salicylates and glucocorticosteroids, which increase the likelihood of peptic ulcer and gastrointestinal bleeding, complications may occur due to synergism of action. Simultaneous administration of the drug with other NSAIDs also leads to adverse effects.

In the case of a one-time use of selective serotonin reuptake inhibitors with meloxicam, the occurrence of bleeding in the intestines and stomach increases.

Due to the fact that Movalis contains sorbitol, its simultaneous use with sodium polystyrene sulfonate increases the likelihood of colon necrosis, which can result in death.

When Movalis is combined with serotonin reuptake inhibitors, anticoagulants for internal use, thrombolytic drugs, heparin (systemic use), antiplatelet agents, the likelihood of bleeding due to suppression of platelet function increases.

NSAIDs increase the content of lithium in the blood by reducing the renal excretion of lithium. Therefore, it is necessary to control the concentration of lithium within a few days after the appointment of Movalis and in the event of a change in the dosage of drugs with lithium and their cancellation.

NSAIDs in some cases reduce the tubular secretion of methotrexate, increasing its hematological toxicity. At the same time, the pharmacokinetics of methotrexate remains unchanged. Therefore, the combined use of methotrexate and Movalis at a dosage of more than 15 mg for 7 days is not desirable.

The possibility of an interaction between methotrexate and NSAIDs may occur in people taking methotrexate in low doses, in particular, complications may develop in people with kidney problems. In this regard, it is necessary to constantly monitor the number of cells in the blood and the functioning of the kidneys. In the case of simultaneous use of methotrexate and meloxicam for 3 days, the likelihood of an increase in the toxicity of methotrexate increases.

Taking NSAIDs along with diuretics in the event of dehydration can lead to acute renal failure.

NSAIDs reduce the effect of intrauterine contraceptives.

Antihypertensive drugs (diuretics, beta-blockers, vasodilators, ACE inhibitors, inhibitors), NSAIDs reduce the effect of antihypertensive drugs, due to a slowdown in the effectiveness of prostaglandins that have a vasodilatory effect.